Entering text into the input field will update the search result below

VistaGen up 10% premarket on advancement of AV-101 in MDD

Oct. 08, 2019 9:19 AM ETVistagen Therapeutics, Inc. (VTGN) StockVTGNBy: Douglas W. House, SA News Editor
  • Thinly traded nano cap VistaGen Therapeutics (NASDAQ:VTGN) is up 10% premarket on light volume following its announcement that the last participant has completed dosing in its Phase 2 ELEVATE clinical trial evaluating AV-101 for the adjunctive treatment of major depressive disorder (MDD). Topline results should be available before year-end.

Recommended For You

More Trending News

About VTGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VTGN--
Vistagen Therapeutics, Inc.